Growth Metrics

Scholar Rock Holding (SRRK) Change in Accured Expenses (2017 - 2026)

Scholar Rock Holding's quarterly Change in Accured Expenses came in at $4.7 million in Q1 2026, up 236.76% year-on-year from $1.4 million in Q1 2025, and up 145.48% quarter-over-quarter from -$10.3 million in Q4 2025.

Scholar Rock Holding has reported Change in Accured Expenses for 10 years, with the latest figure at $4.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Change in Accured Expenses rose 236.76% year-over-year to $4.7 million; the trailing twelve-month figure through Mar 2026 stood at $16.6 million (up 170.27% YoY), and the FY2025 full-year result was $8.5 million, down 19.31% from the prior year.
  • Change in Accured Expenses for Q1 2026 stood at $4.7 million, up from -$10.3 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $16.4 million in Q2 2025, with the low at -$10.3 million in Q4 2025.
  • Average Change in Accured Expenses over 5 years is $1.6 million, with a median of $1.6 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses reached 3230.83% in 2025, while the deepest fall reached 663.35% in 2025.
  • Tracing SRRK's Change in Accured Expenses over 5 years: stood at $1.6 million in 2022, then jumped by 91.26% to $3.0 million in 2023, then sank by 39.01% to $1.8 million in 2024, then plunged by 663.35% to -$10.3 million in 2025, then soared by 145.48% to $4.7 million in 2026.
  • The last three Change in Accured Expenses figures came in at $4.7 million (Q1 2026), -$10.3 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Accured Expenses (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 931,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 70.50 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 107.70 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -176.03 Mn
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 4.68 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4.68 Mn
Mar 31, 2026 4.68 Mn
Dec 31, 2025 -10.30 Mn
Dec 31, 2025 -10.30 Mn
Sep 30, 2025 5.80 Mn
Sep 30, 2025 5.80 Mn
Jun 30, 2025 16.42 Mn
Jun 30, 2025 16.42 Mn
Mar 31, 2025 -3.43 Mn
Mar 31, 2025 -3.43 Mn
Dec 31, 2024 1.83 Mn
Dec 31, 2024 1.83 Mn
Sep 30, 2024 7.25 Mn
Sep 30, 2024 7.25 Mn
Jun 30, 2024 493,000.00
Jun 30, 2024 493,000.00
Mar 31, 2024 963,000.00
Mar 31, 2024 963,000.00
Dec 31, 2023 3.00 Mn
Dec 31, 2023 3.00 Mn
Sep 30, 2023 3.59 Mn
Sep 30, 2023 3.59 Mn
Jun 30, 2023 -925,000.00
Jun 30, 2023 -925,000.00
Mar 31, 2023 -9.59 Mn
Mar 31, 2023 -9.59 Mn
Dec 31, 2022 1.57 Mn
Dec 31, 2022 1.57 Mn
Sep 30, 2022 5.31 Mn
Sep 30, 2022 5.31 Mn
Jun 30, 2022 1.60 Mn
Jun 30, 2022 1.60 Mn
Mar 31, 2022 -1.58 Mn
Mar 31, 2022 -1.58 Mn
Dec 31, 2021 -457,000.00
Dec 31, 2021 -457,000.00
Sep 30, 2021 2.89 Mn
Sep 30, 2021 2.89 Mn
Jun 30, 2021 721,000.00
Jun 30, 2021 721,000.00
Mar 31, 2021 506,000.00
Mar 31, 2021 506,000.00
Dec 31, 2020 3.23 Mn
Dec 31, 2020 3.23 Mn
Sep 30, 2020 3.24 Mn
Sep 30, 2020 3.24 Mn
Jun 30, 2020 857,000.00
Jun 30, 2020 857,000.00
Mar 31, 2020 -2.23 Mn
Mar 31, 2020 -2.23 Mn
Dec 31, 2019 1.47 Mn
Dec 31, 2019 1.47 Mn
Sep 30, 2019 2.76 Mn
Sep 30, 2019 2.76 Mn
Jun 30, 2019 1.25 Mn
Jun 30, 2019 1.25 Mn
Mar 31, 2019 -3.02 Mn
Mar 31, 2019 -3.02 Mn
Dec 31, 2018 3.82 Mn
Dec 31, 2018 3.82 Mn
Sep 30, 2018 352,000.00
Sep 30, 2018 352,000.00
Jun 30, 2018 1.46 Mn
Jun 30, 2018 1.46 Mn
Mar 31, 2018 -1.27 Mn
Mar 31, 2018 -1.27 Mn
Dec 31, 2017 1.47 Mn
Dec 31, 2017 1.47 Mn
Sep 30, 2017 98,000.00
Sep 30, 2017 98,000.00